Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $5.1 million.

  • Entrada Therapeutics' Share-based Compensation rose 526.75% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.0 million, marking a year-over-year increase of 1697.35%. This contributed to the annual value of $17.9 million for FY2024, which is 3664.1% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Share-based Compensation is $5.1 million, which was up 526.75% from $5.0 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Share-based Compensation high stood at $5.1 million for Q3 2025, and its period low was $1.8 million during Q1 2022.
  • Over the past 4 years, Entrada Therapeutics' median Share-based Compensation value was $3.7 million (recorded in 2024), while the average stood at $3.7 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Share-based Compensation surged by 5356.74% in 2023, and later skyrocketed by 526.75% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Share-based Compensation (Quarter) stood at $2.9 million in 2022, then soared by 33.28% to $3.8 million in 2023, then grew by 22.36% to $4.7 million in 2024, then increased by 8.85% to $5.1 million in 2025.
  • Its Share-based Compensation stands at $5.1 million for Q3 2025, versus $5.0 million for Q2 2025 and $5.1 million for Q1 2025.